Last reviewed · How we verify
CSII alone
At a glance
| Generic name | CSII alone |
|---|---|
| Also known as | CSII |
| Sponsor | Sun Yat-sen University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Dual-hormone Artificial Pancreas Versus Single-hormone Under Exercise and a Meal Challenge (NA)
- Inflammatory Response to CSII Catheters in a Tummy Tuck Model (NA)
- Effects of Sequential Treatment Based on Lina/MET After Short-term Intensive Insulin in Newly Diagnosed Type 2 Diabetes (PHASE4)
- A Study of U-500 Insulin (LY041001) in Participants With Type 2 Diabetes (PHASE1)
- cArdiopulmonary exerCise Test Assessing Multiple biOmarkers and Hormones iN Type 1 diabetEs Under Different Circumstances (NA)
- CSII Versus MDI in Pregnant Women With Type 2 Diabetes (NA)
- Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump (PHASE4)
- Intensive Versus Standard One Year Monitoring on Glycaemic Control After Initiating CSII in Children With DT1. DEEP Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CSII alone CI brief — competitive landscape report
- CSII alone updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI